期刊文献+

抗P-糖蛋白多肽模拟物的设计、合成与活性评价 被引量:2

Structure-based design, synthesis and evaluation of bioactivity of anti-P-gp peptide mimetic
下载PDF
导出
摘要 目的 设计、合成抗P 糖蛋白抗体 (PHMA0 2 )的多肽模拟物 ,测定其与P gp结合活性。方法 模建出PHMA0 2的互补决定簇 (complementarity determiningregion ,CDR)三维结构 ,构建出抗P gp的多肽模拟物。流式细胞仪测定其活性。结果 该模拟物竞争P gp抗体与P gp结合 ,并部分阻断P gp药物外排泵的功能。结果显示抗P gp肽模拟物对P gp具有相同结合活性。结论 根据抗体CDR区的构象特征可以构建具有生物活性的肽模拟物。 Aim To design and evaluate the small peptide mimetic of anti-P-glycoprotein ( P-gp ) antibody (PHMA02 ). Methods From the three dementional structure analysis of computer modeling of PHMA02 CDR loops, a small peptide mimetic was designed and determined by flow cytometry. Results Anti-P-gp peptide mimetic functionally similar to PHMA02 was developed. The peptide mimetic competitively inhibits PHMA02 binding to P-gp and partially block the P-gp function as a drug efflux pump in K562/A02 cells. Conclusion ...
出处 《药学学报》 CAS CSCD 北大核心 2003年第11期826-830,共5页 Acta Pharmaceutica Sinica
基金 "十五"国家高技术研究发展计划 (863计划 )资助项目 (2 0 0 2AA2Z3 46D) 国家自然科学基金资助项目(3 990 0 186)
关键词 多药耐药 P-糖蛋白 肽模拟物 multidrug resistance glycoprotein peptide mimetic
  • 相关文献

参考文献11

  • 1[1]Simon SM, Schindler M. Cell biological mechanism of multidrug resistance in tumors [J]. Proc Natl Acad Sci USA, 1994,91(9):3497-3504.
  • 2[2]Chan HS, Haddad G, Thorner PS, et al. P-Glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma [J]. N Engl J Med, 1991,325(23):1608-1614.
  • 3[3]Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer, mechanisms, reversal using modulatiors of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J]. Eur J Pharm Sci, 2000,11(4):265-283.
  • 4[4]Twentyman PR. Cyclosporins as drug resistance modifiers [J]. Biomhem Pharmacol, 1992,43(1):109-117.
  • 5[5]Dougall WC, Peterson NC, Greene MI. Antibody-structure-based design of pharmacological agents [J]. TIBTECH, 1994,12(9):372-379.
  • 6[6]Williams WV, Kieber-Emmons T, Vonfeld D, et al. Design of bioactive peptides based on antibody hypervariable region structures [J]. J Biol Chem, 1991,266(8):5182-5190.
  • 7[7]Monfardini C, Kieber-Emmons T, Voet D, et al. Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides [J]. J Biol Chem, 1996,271(6):2966-2971.
  • 8[8]Levi M, Sallberg M, Ullaruden, et al. A complementarily-determining region synthetic peptide acts as a mini antibody and neutralizes human immunodeficiency virus type-1 in vitro [J]. Proc Natl Acad Sci USA, 1993,90(10):4374-4378.
  • 9[9]Xiong DS, Yang CZ, Shao XF, et al. Preparation and identification of anti-P-glycoprotein [J]. Chin J Hematol (中华血液学杂志), 1999,20(6):326-330.
  • 10[10]Yang CZ, Luan FJ, Xiong DS, et al. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicine [J]. Acta Pharmacol Sin, 1995,16(4):333-337.

同被引文献3

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部